Pozo-Rosich, Patricia
Samaan, Karen H. http://orcid.org/0000-0003-2780-9232
Schwedt, Todd J.
Nicholson, Robert A.
Rettiganti, Mallikarjuna
Pearlman, Eric M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Documents that mention this clinical trial
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Documents that mention this clinical trial
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
https://doi.org/10.1007/s11136-020-02623-1
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 9 December 2020
Accepted: 12 March 2021
First Online: 5 May 2021